CSFB Lifts Longs Drug Opinion

Analyst Jack Murphy cites a management change and lower risk of missing EPS estimates over the next two to four quarters

Longs Drugs Stores (LDG ) reported $0.58 vs. $0.63 Q4 EPS from operations despite a 1.4% same-store sales rise and a 9% increase in total sales. CS First Boston upgraded the shares to hold from sell.

To continue reading this article you must be a Bloomberg Professional Service Subscriber.